Wei Li

Transforming the discovery of oral small molecule therapeutics At QuantX, we leverage the power of computation and modeling to accelerate the discovery of superior medicines for validated targets in immunology and inflammation. Interested in joining our mission to discover breakthrough medicines? Reach out to inquire about vacancies!

Pediatrix® Medical Group, Inc. (Pediatrix) is the nation’s leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by more than 20 pediatric subspecialties, as well as pediatric primary and urgent care clinics. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through more than 5,000 affiliated physicians and other clinicians in 37 states. 

Pediatrix Therapeutics is a pediatrics-focused biotechnology company based in China. Our aspiration is to bring high quality, pediatric-friendly and affordable therapeutics and healthcare products to children and families, leveraging the global development and licensing partnerships to grow our product portfolio. With incomparable expertise in pediatric market in China, we strive to improve the overall clinical care and experience for Chinese pediatric patients. Pediatrix Therapeutics, a company jointly founded in 2021 by Eight Roads, F-Prime Capital, and Creacion Ventures, has already completed its Series A funding round. We have established offices in Shanghai and Beijing, and is currently building an R&D center in Hangzhou, to enhance R&D, manufacturing and commercialization efforts and provide advanced pediatric solutions in China.

Frontera is a leader in life-changing therapeutics that reach patients around the globe. Because of our innovative development platform, our treatments are accessible to patients regardless of geography or livelihood. Frontera's rich product pipeline covers multiple therapeutic areas and is in various stages of development.

Dewpoint is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Merck, and Pfizer. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable. 

Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas. Learn more at www.kymeratx.com

Ocumension Therapeutics established in May 2018, is a company which focuses on the development of ophthalmic medications. The management team of the company possesses extensive experience in R&D, clinical trials, marketing and promotion, and commercial operation. With our ocular disease focus, the company strives to continuously provide important needed therapies to Chinese patients using innovative products derived from both inhouse R&D and strategic alliance with global partners.

CStone (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received nine NDA approvals for four drugs. Multiple late-stage drug candidates are now under pivotal clinical trials or registration. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 5 assets in Phase III or pivotal clinical trials, and additional 14 molecules in to clinical trials. TYVYT® was included in the National Reimbursement Drug List (NRDL) in 2019 as the only PD-1 in that year and was also the first PD-1 inhibitor included in NRDL historically. Innovent has built a biopharmaceutical production facility that operates under global standards. The design and operation of the clinical and commercial facilities are in compliance with the cGMP standards of NMPA, FDA and EMA. The existing production lines have already passed GMP audits by an international pharmaceutical company. Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic cooperation with Eli Lilly, Adimab, Incyte, Hanmi and other international pharmaceutical companies.

Transforming the discovery of oral small molecule therapeutics At QuantX, we leverage the power of computation and modeling to accelerate the discovery of superior medicines for validated targets in immunology and inflammation. Interested in joining our mission to discover breakthrough medicines? Reach out to inquire about vacancies!

Pediatrix® Medical Group, Inc. (Pediatrix) is the nation’s leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by more than 20 pediatric subspecialties, as well as pediatric primary and urgent care clinics. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through more than 5,000 affiliated physicians and other clinicians in 37 states. 

Pediatrix Therapeutics is a pediatrics-focused biotechnology company based in China. Our aspiration is to bring high quality, pediatric-friendly and affordable therapeutics and healthcare products to children and families, leveraging the global development and licensing partnerships to grow our product portfolio. With incomparable expertise in pediatric market in China, we strive to improve the overall clinical care and experience for Chinese pediatric patients. Pediatrix Therapeutics, a company jointly founded in 2021 by Eight Roads, F-Prime Capital, and Creacion Ventures, has already completed its Series A funding round. We have established offices in Shanghai and Beijing, and is currently building an R&D center in Hangzhou, to enhance R&D, manufacturing and commercialization efforts and provide advanced pediatric solutions in China.

Frontera is a leader in life-changing therapeutics that reach patients around the globe. Because of our innovative development platform, our treatments are accessible to patients regardless of geography or livelihood. Frontera's rich product pipeline covers multiple therapeutic areas and is in various stages of development.